- Home
- PEN vs MDGL Comparison
PEN vs MDGL Comparison
Compare PEN & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEN
- MDGL
- Stock Information
- Founded
- PEN 2004
- MDGL 2011
- Country
- PEN United States
- MDGL United States
- Employees
- PEN N/A
- MDGL N/A
- Industry
- PEN Medical/Dental Instruments
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- PEN Health Care
- MDGL Health Care
- Exchange
- PEN Nasdaq
- MDGL Nasdaq
- Market Cap
- PEN 9.7B
- MDGL 9.6B
- IPO Year
- PEN 2015
- MDGL N/A
- Fundamental
- Price
- PEN $255.03
- MDGL $437.10
- Analyst Decision
- PEN Strong Buy
- MDGL Strong Buy
- Analyst Count
- PEN 16
- MDGL 10
- Target Price
- PEN $303.44
- MDGL $512.44
- AVG Volume (30 Days)
- PEN 368.1K
- MDGL 310.9K
- Earning Date
- PEN 11-05-2025
- MDGL 10-30-2025
- Dividend Yield
- PEN N/A
- MDGL N/A
- EPS Growth
- PEN 916.05
- MDGL N/A
- EPS
- PEN 3.74
- MDGL N/A
- Revenue
- PEN $1,280,152,000.00
- MDGL $515,547,000.00
- Revenue This Year
- PEN $15.52
- MDGL $394.08
- Revenue Next Year
- PEN $14.20
- MDGL $61.80
- P/E Ratio
- PEN $68.19
- MDGL N/A
- Revenue Growth
- PEN 12.92
- MDGL 3421.98
- 52 Week Low
- PEN $198.68
- MDGL $200.63
- 52 Week High
- PEN $310.00
- MDGL $463.63
- Technical
- Relative Strength Index (RSI)
- PEN 49.01
- MDGL 55.82
- Support Level
- PEN $245.13
- MDGL $416.29
- Resistance Level
- PEN $265.51
- MDGL $444.87
- Average True Range (ATR)
- PEN 8.05
- MDGL 15.69
- MACD
- PEN 0.09
- MDGL -3.87
- Stochastic Oscillator
- PEN 54.61
- MDGL 43.96
About PEN Penumbra Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.